The Incyte Ingenuity Award Program

Supporting the GVHD community

trophy icon

The 2021 Incyte Ingenuity Award program recipients have been selected! Find out about the award-winning projects

Learn more

 

Introducing the 2021 Incyte Ingenuity Award Program Recipients!

We are pleased to announce that Memorial Sloan Kettering Cancer Center and the Aplastic Anemia and MDS International Foundation are the recipients for the 2021 Incyte Ingenuity Award Program! Both proposals demonstrate clear steps to address the unique challenges faced by patients with graft-versus-host disease (GVHD), as well as their caregivers and providers.

Memorial Sloan Kettering Cancer Center has received the $100,000 award, as its proposal showcased clear dedication to those suffering from GVHD. Its project, the GVHD-Focused Telehealth Clinic, aims to expand access and provide remote specialized GVHD care to new patients within and outside its traditional area to address healthcare disparities that affect medically underserved communities.

Aplastic Anemia and MDS International Foundation has received the $35,000 award, by demonstrating unwavering commitment to improving the lives of people with GVHD, as evidenced by its project, called the GVHD Interactive Provider Network. This network aims to increase access to expert advice and mentoring by connecting GVHD specialists with community-based providers to share expertise and discuss cases to improve care outside of major academic centers.

Learn more about the 2021
award-winning projects

See the recipients

The Incyte Ingenuity Award program is not currently accepting applications.

Applications will re-open in the first half of 2022.

In the meantime, watch the following video to hear the 2020 award recipient explain how devastating GVHD can be for patients, and how the Incyte Ingenuity Award program aims to support people living with GVHD, as well as their caregivers and physicians.

Eligibility

Eligibility Information

The following groups and individuals are eligible to apply for the Incyte Ingenuity Awards:

Image of hands holding heart

Non-profit 501(c)(3), patient, policy, and caregiver organizations

Image of caduceus

Healthcare providers and mid-level/junior faculty of healthcare organizations*

Image of two people

Individuals or other companies collaborating with these organizations and institutions**

Programs must be independent of any ongoing activities, with the exception of considerably expanding an existing program. Additionally, programs cannot include indirect costs with the proposed budget. To be eligible, you and your organization must be US based (including Washington DC and Puerto Rico).

*Applications must be submitted in the name of an institution, not on behalf of an individual.

**Individuals or other companies interested in applying must partner with either a non-profit organization or a healthcare facility (i.e., hospitals, academic research centers, etc.) to be eligible.

Applications will be disqualified if:

  • Focus is on a particular therapeutic agent, translational research, or clinical research that is interventional in nature.
  • Organization is improperly identified as a 501(c)(3) organization.
  • Application is submitted by a healthcare professional as an individual (individuals will need to partner with a not-for-profit or other organization to be considered).
  • Defined scope does not serve or plan to address a specific need of the GVHD community.
  • Request in funding exceeds 25% of an organization’s overall funding and/or includes indirect costs.
  • Application is submitted by an employee of Incyte, VOZ Advisors, and/or other vendors, or members of the immediate family of any such persons.
  • Program is duplicated, with multiple copies of an application submitted by the same organization.
  • Program exceeds the maximum application limit per organization (more than five).
  • Program is based on an existing initiative, with no evidence of ingenuity.

Incyte reserves the right to modify the eligibility requirements at any time.

Have additional questions? Check out our FAQ page.

Meet the Judges

Meet the Judges

Meet our 2021 Incyte Ingenuity Award program judging panel!

Image of Shrina Duggal

Shrina Duggal, PharmD, BCOP

Dr Shrina Duggal, PharmD, BCOP, is a clinical pharmacy specialist in hematology/oncology/BMT at the University of Pittsburgh Medical Center Hillman Cancer Center. She has been working as a clinical pharmacy specialist at UPMC Hillman Cancer Center since 2007 and has experience in both the inpatient and outpatient settings, managing patients with hematological malignancies and solid tumors and, most recently, in the management of patients receiving various immunotherapy agents. Dr Duggal acts as faculty mentor and adjunct faculty member at West Virginia University School of Pharmacy. She has lectured and taught extensively across the country and holds multiple preceptorships in experiential learning, pharmacy practice, and hematology/oncology/SCT specialty residencies. Dr Duggal is a member of the Hematology Oncology Pharmacists Association, American College of Clinical Pharmacy, and American Society for Transplantation and Cellular Therapy.

More
Less
Image of Gerald Cowden

Gerald Cowden, J.D.

Gerald W. Cowden is a practicing attorney. He has been representing entrepreneurs, high-growth companies, and financial investors for more than 40 years. Cowden received his BA at Washington and Jefferson College and his JD at the University of Akron School of Law. In addition to his professional career as a Partner at Cowden & Humphrey, he is also a cofounder of a patient advocacy group, the Meredith A. Cowden Foundation. Cowden is currently and has been a member or a trustee of numerous prominent state and national business associations or committees including the Corporate Sections of the Cleveland and Akron Bar Associations, the Corporation Law Committee and Taxation Law Committee of the Ohio Bar Association, and the American Bar Association. In addition, he has served as a judge in the Ernst & Young Entrepreneur of the Year Program and on many corporate and advisory boards for both clients and nonclients. In 2007, in conjunction with his daughter Meredith and his wife Marti, he cofounded the Meredith A. Cowden Foundation. The Foundation’s mission is to raise awareness of the impact of leukemia and GVHD, to fund research for GVHD, and to provide financial support for nonmedical expenses associated with blood cancers. Every year the Cowden Foundation holds the GVHD National Symposium where research physicians present the latest and greatest methods to help patients living with GVHD. In 2019, the Cowden Foundation received the Lifeblood Award from the Leukemia & Lymphoma Society. Most recently, in February 2020, Cowden received the Public Service Award from the American Society of Transplantation and Cellular Therapy to honor the work of the Cowden Foundation. Cowden lives in Akron with his wife of 50 years and has two daughters, Margaux and Meredith.

More
Less
Image of Navneet Majhail

Navneet Majhail, MBBS, MD, MS

Dr Navneet Majhail, MBBS, MD, MS, is the Director of the Blood & Marrow Transplant Program at the Taussig Cancer Institute, Cleveland Clinic, and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio. He has also previously served as President of the American Society for Transplantation and Cellular Therapy. Dr Majhail specializes in the care of adult patients receiving blood and marrow transplantation. His research focuses on transplant outcomes, health services and health policy issues in blood and marrow transplantation, and quality of life and late effects in transplant survivors, including patients with graft-versus-host disease. His research has been funded by the Patient Centered Outcomes Research Institute and the National Institutes of Health.  

More
Less
Image of Peggy Burkhard

Peggy Burkhard

Peggy Burkhard is the Executive Director of the National Bone Marrow Transplant Link (nbmtLINK), an independent non-profit organization, founded in 1992. The mission of the nbmtLINK is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant and CAR-T cellular therapy from diagnosis through survivorship by providing vital information and personalized support services. Burkhard began her career in New York City in the publishing business before moving to Michigan and working for several organizations and non-profits as a public relations and marketing professional. Prior to joining nbmtLINK, Burkhard had spent the last 20 years promoting organ, tissue, and eye donation with the Donate Life Coalition of Michigan. The nbmtLINK provides several services and resources designed to meet the needs of bone marrow/stem cell transplant patients, survivors, caregivers, and health professionals around the globe. Various services include several original publications written in easy-to-understand language, a Peer Support On Call program, an award-winning Marrow Masters podcast, popular Lunch & Learn monthly call-in programs, a Celebrating Second Birthdays program, webinars and podcasts, and an original Emmy-award winning documentary, The New Normal. Now in its 29th year, the National Bone Marrow Transplant Link continues to provide educational, psychosocial, and personalized support to people facing this daunting medical journey. The nbmtLINK has formed alliances with many of the major transplant centers in the US. These LINK partnerships provide an avenue of communication between the organization and these hospitals. Additionally, the LINK collaborates with other major cancer-related organizations such as the Meredith A. Cowden Foundation, Leukemia & Lymphoma Society, Be the Match, DKMS, and the National Institutes of Health.

More
Less
Image of Miguel-Angel Perales

Miguel-Angel Perales, MD

Dr Miguel-Angel Perales is the Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York, as well as an Associate Professor of Medicine at Weill Cornell Medical College. He is an internationally recognized leader in the field of hematopoietic stem cell transplantation and cellular therapy and serves as Chair of the Alliance for Clinical Trials in Oncology Transplantation and Cell Based Therapies Committee, as Vice-Chair of the Board of Directors of Be The Match (National Marrow Donor Program - NMDP), and Vice-President of the American Society for Transplantation and Cellular Therapy (ASTCT, former ASBMT). He also holds leadership positions and has been extensively involved in activities of the Center for International Blood and Marrow Transplant Research (CIBMTR) and Blood and Marrow Transplantation Clinical Trials Network (BMT CTN). Dr Perales received his MD from the Free University of Brussels and completed his postdoctoral training at the Tufts Medical Center and Memorial Sloan Kettering Cancer Center. Dr Perales has over 250 publications including peer-reviewed articles, position papers, guidelines, book chapters, editorials, and invited reviews. He has been an invited speaker at numerous national and international meetings over the past 20 years.

More
Less
copy

Incyte will not provide any advice or input during the judging process, and all decisions made by the judging panel are final. These judges will receive compensation for their services from Incyte, based on fair market value.

Judging Criteria

Judging Criteria

Our independent judging panel will consider the following criteria when evaluating each award application:

Does the applicant meet the eligibility requirements?

Did the applicant collaborate with any other organizations to optimize the success of the initiative?

Does the application contain all of the necessary details and supporting documents?

Does the proposal exhibit a thoughtful, creative and innovative approach to address a specific need within the GVHD community?

Can the proposal be completed within the one-year time frame?

Does the proposal demonstrate a clear purpose and rationale?

Does the proposal include a realistic and appropriate budget?

Does the proposal have clear and measurable outcomes? Does it follow the SMART (specific, measurable, achievable, realistic, timely) methodology for setting goals?

Incyte reserves the right to change the judging criteria at any time.